This report covers news and updates in the management of thyroid cancer, with a special focus on differentiated thyroid cancer (DTC) and of the management of aggressive and refractory cases. Along with a general overview of thyroid cancer and its management, the report specifically highlights news from the 84th annual meeting of the American Thyroid Association (ATA), which took place from October 29 – November 2, 2014 in Coronado, California. Chaired by Drs. Michael Tuttle and Fredric Wondisford, the meeting provided an outstanding scientific educational experience for over 1200 attendees.
Specialists are still awaiting the new ata guidelines for DTC management. Even without updated guidelines, the content/news from the ATA meeting is worth sharing. Radioactive iodine-refractory differentiated thyroid cancer (RAI-r DTC) has been identified as an area of particular interest.
The report content that follows is drawn from ATA and is augmented with commentary and insights from CARE Faculty member, Dr. Andrée Boucher (endocrinologist, QC).